The availability of a rough draft of the predicted human proteome allows an
evaluation of the extent to which the predicted and biochemical functions
of proteins are in alignment, and the roles of different technologies and a
pproaches to understanding human diseases and instantiating therapeutics. M
icroarray technologies at the transcriptomic and proteomic levels can be hi
gh throughput and excellent for diagnostic purposes, but their informationa
l outputs are inferior in quality to those emerging from the co- and post-t
ranslational levels and from antibody-based molecular anatomy. It is now ab
undantly clear that data transfer between the transcriptome and proteome is
not straightforward, and that increasing emphasis needs to be placed on pu
re proteomic approaches at the structural, quantitative, cell biological an
d phenomic levels, with special focus on embryogenic and foetal processes.
Finally, the precision genetic engineering that is required to evaluate the
functional significance of context-dependent protein interactions underpin
ned by post-translational modifications and proteolytic cleavage events, is
still too time consuming and rudimentary to be implemented on a large scal
e in the mouse, and basic principles and first order networks will need to
be sorted out in even simpler model systems such as Drosophila.